📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
36 announcements match the current filters (relevance ≥ 5).
CORONA Remedies FY26 PAT Surges 33.4% to ₹199.4 Cr; Revenue Grows 17.3%
CORONA Remedies reported a robust financial performance for FY26, with revenue increasing 17.3% to ₹1,403.2 crore and PAT growing 33.4% to ₹199.4 crore. The company's EBITDA margins improved by 85 bps to 20.9%, driven by operational efficiencies and a strong focus on chronic therapies, which now contribute 71.9% of total revenue. Strategic moves included the acquisition of WOKADINE to enter the ₹648 crore Povidone Iodine market and the relaunch of key brands in women's health and cardiovascular segments. The company also improved its domestic market ranking to 27th, up from 32nd three years ago.
Key Highlights
FY26 Revenue grew 17.3% YoY to ₹1,403.2 Cr, with Q4FY26 revenue rising 20.2% to ₹353.1 Cr.
Full-year PAT increased 33.4% to ₹199.4 Cr, while Q4FY26 PAT surged 43.7% to ₹45.3 Cr.
EBITDA margins expanded by 85 bps to 20.9% for FY26, reflecting strong operating leverage.
Acquired WOKADINE brand via internal accruals, marking entry into the ₹648 Cr Povidone Iodine market.
Chronic therapy segment remains dominant, contributing 71.9% of total revenue in FY26.
👀 What to Watch
Investors should take note of the company's consistent margin expansion and successful brand-building strategy, which has led to two brands crossing the ₹100 Cr MAT milestone. The entry into new markets via EAEU-GMP certification and the WOKADINE acquisition provide clear catalysts for future growth.
Corona Remedies Approves FY26 Results, Recommends ₹10 Final Dividend
Corona Remedies has approved its audited financial results for the fourth quarter and full year ended March 31, 2026, with the auditors providing an unmodified opinion. The Board recommended a final dividend of ₹10 per share (100% of face value), setting June 19, 2026, as the record date. Additionally, the company is transitioning its statutory auditors to Walker Chandiok & Co LLP for a five-year term starting FY 2026-27. Dr. Kirtikumar Mehta has also been re-appointed as Chairman for another five-year term starting April 2027.
Key Highlights
Recommended a final dividend of ₹10 per equity share (100% of face value) for FY 2025-26.
Fixed June 19, 2026, as the record date for dividend entitlement, with payment scheduled by August 07, 2026.
Appointed M/s. Walker Chandiok & Co LLP as Statutory Auditors for a 5-year period from FY27 to FY31.
Re-appointed Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for five years from April 1, 2027.
Auditors issued an unmodified opinion on both standalone and consolidated financial results for the year ended March 31, 2026.
👀 What to Watch
Investors should note the ₹10 dividend payout and the upcoming record date of June 19. The appointment of a major audit firm like Walker Chandiok & Co LLP is a positive signal for corporate governance.
CORONA Remedies Acquires Wokadine® from Dr. Reddy’s; Enters INR 648 Cr Market
CORONA Remedies has announced the strategic acquisition of the Wokadine® brand from Dr. Reddy’s Laboratories, marking its fifth acquisition to date. Wokadine® is currently ranked #2 in the Indian Povidone Iodine market, which is valued at approximately INR 648 crore. The transaction, which includes 14 SKUs, will be entirely funded through internal accruals and cash reserves, ensuring no additional debt burden. This acquisition allows CORONA to leverage its existing distribution network and expand its presence among surgeons, ENT specialists, and gynecologists.
Key Highlights
Acquisition of Wokadine®, the #2 ranked brand in India's Povidone Iodine market
Entry into the INR 648 crore Povidone Iodine therapeutic segment with 14 SKUs
Transaction is fully funded through internal accruals and cash, maintaining a healthy balance sheet
Strategic synergy with existing focus areas including Surgeons, ENT, and Gynaecologists
Marks the 5th acquisition for CORONA Remedies, demonstrating a consistent inorganic growth strategy
👀 What to Watch
Investors should view this as a positive growth move that strengthens the company's portfolio without leveraging the balance sheet. Monitor the integration and subsequent revenue growth from the Wokadine® brand in upcoming quarterly results.
CORONA Remedies Q3 FY'26 Revenue Up 15% to ₹342 Cr; PAT Grows 24%
CORONA Remedies reported a strong Q3 FY'26 with revenue growing 15% YoY to ₹342 crores and adjusted PAT rising 24% to ₹56 crores. The company significantly outperformed the Indian Pharmaceutical Market (IPM) with an 18.9% growth rate, securing the 28th rank among top pharma firms. EBITDA margins improved by 100 bps to 24.3%, supported by a high contribution from the chronic and semi-chronic segments which now account for over 70% of revenue. Management maintained a positive outlook, citing upcoming commercialization of acquired Bayer brands and new EAEU GMP accreditation for international expansion.
Key Highlights
Q3 FY'26 revenue increased 15% YoY to ₹342 crores, while 9M FY'26 revenue reached ₹1,050 crores.
EBITDA margins expanded by 100 bps to 24.3% in Q3, with 9M PAT growing 31% YoY to ₹154 crores.
Outperformed IPM growth of 9.6% by recording 18.9% growth, moving up to the 28th rank in the market.
Received EAEU GMP accreditation, opening access to a $25 billion pharmaceutical market across five member countries.
Commercialization of the Bayer brand portfolio is set to begin in Q4 FY'26 with the launch of Noklot Plus.
👀 What to Watch
Investors should view this as a strong growth play given the company's consistent outperformance of the broader market and healthy return ratios like an ROE of 31%. The integration of Bayer brands and international expansion into EAEU markets provide clear catalysts for sustained earnings growth.
CORONA Remedies Q3 FY26: Adjusted PAT Up 23.7% to ₹55.6 Cr; EBITDA Margins Expand to 24.3%
CORONA Remedies reported a strong Q3 FY26 performance with revenue growing 15% YoY to ₹342.4 crore and adjusted PAT rising 23.7% to ₹55.6 crore. The company demonstrated significant operational efficiency, with EBITDA margins expanding by 100 bps to 24.3% and 9M FY26 ROCE standing at a robust 48.0%. A key growth catalyst is the recent EAEU-GMP certification for its Bhayla facility, which opens access to a USD 25 billion market across five Eurasian countries including Russia. The business remains heavily skewed towards high-margin chronic therapies, which now contribute 71.6% of total revenue.
Key Highlights
Revenue for 9M FY26 crossed the ₹1,000 Cr milestone, reaching ₹1,050.1 Cr, up 16.3% YoY.
Adjusted PAT for 9M FY26 grew by 30.7% YoY to ₹154.1 Cr, reflecting strong bottom-line momentum.
Chronic therapy segment continues to lead, contributing 71.6% of total revenue in Q3 and 9M FY26.
Bhayla facility received EAEU-GMP certification in January 2026, enabling entry into five key Eurasian markets.
Maintained superior return ratios with 9M FY26 ROE at 31.1% and ROCE at 48.0% (annualized).
👀 What to Watch
Investors should take note of the company's consistent margin expansion and its successful transition into a chronic-heavy portfolio. The recent EAEU-GMP certification provides a significant international growth runway that could re-rate the stock as export revenues scale.
CORONA Remedies Reaffirms CARE A+; Stable Credit Rating for ₹95 Crore Bank Facilities
CARE Ratings has reaffirmed the credit ratings for CORONA Remedies Limited's bank facilities totaling ₹95 crore. The long-term facilities, which were reduced from ₹73 crore to ₹25 crore, maintained a 'CARE A+; Stable' rating. Additionally, the combined long-term and short-term facilities of ₹70 crore were reaffirmed at 'CARE A+; Stable / CARE A1'. This reaffirmation reflects the company's consistent operational and financial performance through FY25 and the first half of FY26.
Key Highlights
CARE Ratings reaffirmed 'CARE A+; Stable' for ₹25 crore long-term bank facilities.
Long-term bank facilities were significantly reduced from ₹73 crore to ₹25 crore, indicating debt reduction.
Reaffirmed 'CARE A+; Stable / CARE A1' for ₹70 crore long-term/short-term bank facilities.
The rating review was based on audited FY25 and unaudited H1FY26 financial performance.
Total rated bank facilities currently stand at ₹95 crore across ICICI Bank and Citi Bank.
👀 What to Watch
The reaffirmation of a high credit rating and the reduction in long-term debt facilities are positive indicators of financial health. Investors should maintain their positions as the company demonstrates stable creditworthiness and disciplined debt management.
Corona Remedies Q3FY26 PAT jumps 23.7% YoY to ₹55.56 Cr; Revenue up 15%
CORONA Remedies reported a strong Q3FY26 with revenue growing 15% YoY to ₹342.42 Cr, outperforming the Indian Pharmaceutical Market (IPM) growth. Adjusted Profit After Tax (PAT) saw a significant rise of 23.7% YoY to ₹55.56 Cr, while 9-month PAT grew by 30.7%. The company maintained robust operational efficiency with an EBITDA margin of 24.3% for the quarter and an impressive annualized RoCE of 48.0%. Management remains optimistic about maintaining a trajectory of 15% revenue and 20% PAT growth going forward.
Key Highlights
Q3FY26 Revenue grew 15.0% YoY to ₹342.42 Cr; 9M Revenue reached ₹1,050.09 Cr.
Adjusted PAT for Q3 rose 23.7% YoY to ₹55.56 Cr, excluding one-time labour code impacts of ₹14.29 Cr.
Strong profitability metrics with Q3 EBITDA margin at 24.3% and 9M annualized RoCE at 48.0%.
Efficient working capital management with Net Working Capital days standing at just 18 days.
9M OCF to EBITDA ratio remains healthy at 86.3%, indicating strong cash flow generation.
👀 What to Watch
Investors should view this performance positively as the company is consistently outperforming the market and delivering high return ratios. The stock warrants a positive outlook given the management's confidence in maintaining a 15-20% growth trajectory and efficient capital utilization.
CORONA Remedies Q3 FY26 PAT Jumps 23.7% YoY to ₹55.56 Cr; Revenue Up 15%
CORONA Remedies reported a strong performance for Q3 FY26, with consolidated revenue growing 15% YoY to ₹342.42 Cr. Adjusted Profit After Tax (PAT) saw a significant increase of 23.7% YoY, reaching ₹55.56 Cr, while the 9-month PAT grew by 30.7%. The company maintained healthy margins with an EBITDA margin of 24.3% for the quarter. Key efficiency metrics remain robust, featuring an annualized RoCE of 48% and a tight working capital cycle of 18 days.
Key Highlights
Consolidated Revenue for Q3 FY26 grew 15% YoY to ₹342.42 Cr, outperforming the Indian Pharmaceutical Market growth.
Adjusted PAT for the quarter rose 23.7% YoY to ₹55.56 Cr, excluding a one-time labor code impact of ₹14.29 Cr.
EBITDA margin stood strong at 24.3% for Q3 FY26, with 9-month EBITDA reaching ₹231.42 Cr.
Operational efficiency is high with an annualized RoCE of 48.0% and RoE of 31.1% for the nine-month period.
Cash flow management remains solid with OCF to EBITDA at 86.3% and net working capital at just 18 days.
👀 What to Watch
Investors should view this as a strong growth signal, as the company is consistently outperforming market growth and maintaining high return ratios. Monitor the upcoming earnings call for guidance on the sustainability of these margins and the impact of the New Labour Code.
CORONA Remedies Secures EAEU-GMP Certification, Accessing USD 25 Billion Market
CORONA Remedies has received the EAEU-GMP certification for its Bhayla, Gujarat facility, enabling entry into five Eurasian nations including Russia and Belarus. This certification provides strategic access to a pharmaceutical market estimated at USD 25 billion through a B2B business model. The expansion focuses on the company's core therapeutic pillars: Women’s Health, Cardio-Diabetes, Pain Management, and Urology. As the fastest-growing company among the top 30 in the Indian Pharmaceutical Market, this move significantly strengthens its international footprint.
Key Highlights
Received EAEU-GMP certification for the finished dosage facility situated at Bhayla, Gujarat
Gains access to a pharmaceutical market estimated at USD 25 billion across five member nations
Entry into Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan under a B2B business model
Identified as the fastest growing company among the top 30 in the Indian Pharmaceutical Market as of September 2025
Strengthens global presence in key therapeutic areas including Women’s Health and Cardio-Diabetes
👀 What to Watch
Investors should monitor the company's ability to convert this certification into revenue-generating B2B partnerships in the Eurasian region. This development is a positive indicator of the company's quality standards and long-term export growth potential.
CORONA Remedies Receives EAEU GMP Certification for Bhayla Facility
CORONA Remedies Limited has successfully obtained the Good Manufacturing Practice (GMP) Certificate of Compliance from the Eurasian Economic Union (EAEU). This certification applies to the company's finished dosage manufacturing facility located in Bhayla, Gujarat. The approval covers a significant economic bloc consisting of five countries: Russia, Kazakhstan, Kyrgyzstan, Belarus, and Armenia. This regulatory milestone is a critical step for the company to begin exporting and marketing its products within these international territories.
Key Highlights
Received GMP Certificate of Compliance from the Eurasian Economic Union (EAEU)
Certification applies to the finished dosage facility situated at Bhayla, Gujarat
Enables market access to 5 countries: Russia, Kazakhstan, Kyrgyzstan, Belarus, and Armenia
Strategic approval paves the way for international expansion and export revenue growth
👀 What to Watch
Investors should monitor the company's progress in securing product-specific registrations in these new markets to gauge the timeline for revenue contribution. This development strengthens the company's long-term export potential and geographic diversification.
CORONA Remedies Targets 15% Revenue and 20% PAT CAGR in Maiden Earnings Call
CORONA Remedies, which listed in December 2025, is positioning itself as a high-growth domestic pharma player with 70% revenue from chronic and semi-chronic segments. The company is currently the fastest-growing among India's top 30 pharma firms, outpacing the market by 1.5x. Management has provided a robust outlook, targeting 15% revenue and 20% PAT growth over the next 3-4 years. Growth will be supported by a new 400 million unit capacity in Gujarat and the integration of seven brands acquired from Bayer Zydus.
Key Highlights
Management targets 15% revenue CAGR and 20% PAT growth over the next 3-4 years.
Acquired 7 brands from Bayer Zydus in July 2025, entering the INR 1,500+ crore anti-platelet market.
Commissioned new capacity of 400 million tablets/capsules at Gujarat facility in December 2025.
Chronic and semi-chronic segments contribute 70% of total revenue with 38 brands exceeding INR 10 crore sales.
Company remains net cash surplus and is one of only three Indian firms to in-license from Ferring Pharmaceuticals.
👀 What to Watch
The stock is a strong growth play in the domestic branded formulations space given the 20% PAT growth guidance. Investors should monitor the ramp-up of the newly commissioned Gujarat facility and the successful integration of the Bayer Zydus portfolio.
CORONA Remedies Outpaces Market with 16.8% Revenue CAGR and 71% Chronic Portfolio Focus
CORONA Remedies, which listed in December 2025, has demonstrated a strong 16.8% revenue CAGR, outperforming the Indian Pharmaceutical Market (IPM) growth by 1.82x. The company has successfully shifted its focus toward chronic therapies, which now account for 71.1% of its portfolio compared to 69.1% in FY23. With a robust manufacturing base and recent capacity expansion of 400 million tablets at its Gujarat facility, the company is scaling its 27 'Engine' brands. Strategic acquisitions from Bayer Zydus and GSK continue to drive market share in high-growth segments like Women's Healthcare and Pain Management.
Key Highlights
Achieved a 16.8% Revenue CAGR, growing at 1.82x the rate of the Indian Pharmaceutical Market (IPM).
Chronic therapy segment contribution rose to 71.1% of total revenue, reflecting a high-margin product mix.
Commenced additional production of 400 million tablets at the EU-GMP certified Gujarat facility on December 22, 2025.
Holds significant market positions including #5 in Pain Management and #6 in Women’s Healthcare in India.
Portfolio includes 71 brands with 27 'Engine' brands, supported by a pan-India distribution network.
👀 What to Watch
Investors should focus on the company's ability to scale its newly added manufacturing capacity and the integration of brands acquired from Bayer Zydus. The high concentration in chronic therapies and domestic market focus provides a defensive yet high-growth profile.
CORONA Remedies Q2 FY26 PAT Jumps 21.8% YoY to ₹52.32 Cr; Revenue Up 15.1%
CORONA Remedies reported a strong financial performance for Q2 FY26, with revenue growing 15.1% YoY to ₹361.13 Cr and PAT increasing 21.8% to ₹52.32 Cr. For the first half of the year (H1 FY26), the company saw a significant 35.1% jump in PAT, reaching ₹98.52 Cr. The company maintained healthy operational efficiency with an EBITDA margin of 21.7% and reported an impressive annualised RoCE of 49.7%. Management highlighted that their growth continues to outperform the Indian Pharmaceutical Market (IPM) through a focus on specialist prescriptions.
Key Highlights
Q2 FY26 Revenue from operations grew 15.1% YoY to ₹361.13 Cr.
H1 FY26 Profit After Tax (PAT) surged 35.1% YoY to ₹98.52 Cr.
Strong return ratios with annualised RoE at 31.1% and RoCE at 49.7%.
Efficient working capital management with Net Working Capital cycle at 23 days.
Healthy cash flow generation with OCF to EBITDA ratio at 76.5%.
👀 What to Watch
The company's high return ratios and efficient working capital cycle make it a strong performer in the mid-cap pharma space. Investors should monitor the earnings call on January 5, 2026, for further outlook on market share gains in core therapeutic segments.
CORONA Remedies Q2FY26 PAT Jumps 21.8% YoY to ₹52.32 Cr; Revenue Up 15.1%
CORONA Remedies reported a strong performance for Q2FY26, with revenue growing 15.1% YoY to ₹361.13 Cr and PAT increasing 21.8% to ₹52.32 Cr. For the first half of FY26, the company showed even stronger momentum with PAT surging 35.1% YoY to ₹98.52 Cr. The company maintained healthy margins with an EBITDA margin of 21.7% in Q2 and reported impressive annualized return ratios, including a RoCE of 49.7%. Management attributed this growth to outperforming the Indian Pharmaceutical Market (IPM) through a focus on specialist prescriptions and core therapeutic segments.
Key Highlights
Q2FY26 Revenue grew 15.1% YoY to ₹361.13 Cr, while H1FY26 Revenue rose 17.0% to ₹707.67 Cr.
Profit After Tax (PAT) for Q2FY26 increased by 21.8% YoY to ₹52.32 Cr.
EBITDA margin for Q2FY26 stood at 21.7% with an EBITDA of ₹78.47 Cr.
Annualized RoCE and RoE for H1FY26 are exceptionally strong at 49.7% and 31.1% respectively.
Efficient working capital management demonstrated by Net Working Capital Days of just 23 days.
👀 What to Watch
The company demonstrates robust growth and industry-leading capital efficiency with a RoCE near 50%, suggesting a strong competitive moat in branded formulations. Investors should monitor the earnings call on January 05, 2026, for management's outlook on sustaining these high return ratios.
CORONA Remedies Q2 FY26 PAT Surges 21.8% YoY to ₹52.32 Cr; Revenue Up 15.1%
CORONA Remedies reported a strong financial performance for Q2 FY26, with consolidated revenue growing 15.1% YoY to ₹361.13 Cr. Profit After Tax (PAT) saw a significant jump of 21.8% YoY to ₹52.32 Cr, while H1 FY26 PAT grew by an impressive 35.1% YoY. The company maintained healthy operational efficiency with an EBITDA margin of 21.7% in Q2 and reported exceptional return ratios, including an annualized RoCE of 49.7%. Management highlighted that the growth outperformed the Indian Pharmaceutical Market (IPM) due to a focus on core therapeutic segments and specialist prescriptions.
Key Highlights
Consolidated Revenue for Q2 FY26 grew 15.1% YoY to ₹361.13 Cr and H1 FY26 grew 17.0% to ₹707.67 Cr
PAT for Q2 FY26 increased by 21.8% YoY to ₹52.32 Cr, while H1 FY26 PAT rose 35.1% to ₹98.52 Cr
Strong operational metrics with Q2 EBITDA margin at 21.7% and H1 annualized RoCE at a robust 49.7%
Efficient working capital management with Net Working Capital Days standing at 23 days
Growth driven by core therapeutic segments including women's healthcare, cardio-diabeto, and pain management
👀 What to Watch
Investors should view these results positively as the company is outperforming the broader pharmaceutical market with high return ratios and efficient capital management. Monitor the upcoming earnings call on January 05, 2026, for further guidance on growth sustainability and expansion plans.
CORONA Remedies Boosts Capacity by 400 Million Units at Bhayla Facility
CORONA Remedies has commenced additional commercial production of tablets and capsules at its Bhayla manufacturing facility as of December 22, 2025. The expansion adds 400 million units to the installed capacity and 240 million units to the available capacity. This move follows a high capacity utilization of 93.58% as of March 2025, where the company produced 561.49 million units against an available capacity of 600 million. Significantly, the entire expansion has been funded through internal accruals, reflecting a strong balance sheet.
Key Highlights
Additional commercial production of tablets/capsules commenced on December 22, 2025.
Installed capacity increased by 400 million units; available capacity increased by 240 million units.
Previous capacity utilization was at a high 93.58%, indicating a clear need for expansion.
The expansion project was funded entirely through internal accruals without external debt.
Strategic move aimed at meeting upcoming market demand and improving supply chain agility.
👀 What to Watch
Investors should view this expansion positively as it addresses capacity constraints and is funded without debt. Monitor the ramp-up of this new capacity and its impact on top-line growth in the next few quarters.
